bioAffinity Technologies, Inc. (BIAF)
| Market Cap | 4.27M |
| Revenue (ttm) | 6.78M |
| Net Income (ttm) | -14.74M |
| Shares Out | 4.49M |
| EPS (ttm) | -20.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 119,175 |
| Open | 1.030 |
| Previous Close | 1.060 |
| Day's Range | 0.950 - 1.030 |
| 52-Week Range | 0.693 - 46.530 |
| Beta | 2.46 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Mar 30, 2026 |
About BIAF
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have... [Read more]
Financial Performance
In 2024, bioAffinity Technologies's revenue was $9.36 million, an increase of 269.68% compared to the previous year's $2.53 million. Losses were -$9.04 million, 13.9% more than in 2023.
Financial StatementsNews
bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AAAAI--bioAffinity Technologies presents research at AAAAI related to identifying drug antibody receptors in sputum for two leading asthma therapies.
bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BAMC--bioAffinity Technologies announced validation study with BAMC to assess deep suction sputum samples for lung cancer detection with CyPath Lung.
New Case Study Highlights Ability of bioAffinity Technologies' CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer
SAN ANTONIO, Texas--(BUSINESS WIRE)---- $BIAF #BIAF--In new case study, CyPath Lung spares elderly woman from an invasive procedure for a suspicious lung nodule discovered on a CT scan.
Clinical Utility of bioAffinity Technologies' CyPath® Lung Test Demonstrated in Real-World Case Study
SAN ANTONIO, Texas--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies shares a new case study that demonstrates how CyPath® Lung supports clinical decision-making in high-risk patients.
bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies appoints nationally recognized pulmonary and lung cancer authorities to its Medical and Scientific Advisory Board.
bioAffinity Technologies' Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity's laboratory, Precision Pathology Laboratory Services, maintains accreditation from the College of American Pathologists.
bioAffinity Technologies' Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #ACS--bioAffinity Technologies will present case studies at NLCRT in which CyPath® Lung identified Stage 1A lung cancer in high-risk patients.
bioAffinity Technologies Reports Third Quarter 2025 Financial Results
SAN ANTONIO--(BUSINESS WIRE)-- #AI--bioAffinity Technologies reports Q3 2025 financial results, achieves 86% increase in CyPath® Lung testing revenue.
bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announced the volume of CyPath® Lung tests processed in October increased by 111% over the 2025 monthly average.
bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
SAN ANTONIO--(BUSINESS WIRE)-- #AI--Australian Patent Office accepts bioAffinity Technologies' patent application for its platform technology to assess lung health and predict disease.
bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies will present research related to its noninvasive CyPath Lung test for lung cancer at CHEST 2025.
bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #AI--The US Patent and Trademark Office will issue BIAF a new patent on its flow cytometry+AI platform that detects lung cancer as early as Stage 1A.
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies received written notice from Nasdaq stating that the Company has regained compliance with continued listing requirements.
WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
JERSEY CITY, N.J. , Oct. 9, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc...
bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies closed on a $1.8 million registered direct offering of common stock.
WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
JERSEY CITY, N.J. , Oct. 8, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc...
bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces a $1.8 million registered direct offering of common stock.
bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Sales of bioAffinity's CyPath® Lung test for lung cancer reached a new high in Q3 2025, representing a 95% increase over the previous quarter.
WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m
JERSEY CITY, N.J. , Sept. 30, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, I...
bioAffinity Technologies Announces Closing of $4.8 Million Public Offering
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies closes $4.8 million public offering.
WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m
JERSEY CITY, N.J. , Sept. 29, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, I...
bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces pricing of $4.8 million public offering.
bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies shares 3 new case studies in which CyPath Lung detected Stage 1A lung cancer or prevented unnecessary invasive procedures.
bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today announced it will effect a 1-for-30 reverse split of its common stock at the opening of trading on September 19, 2025.
Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--CyPath® Lung identifies incidentally found ground-glass lung nodules, leading to early diagnosis and timely treatment.